Why the hold-up?
It a good chance it centres around the future of the other drug in the NEU portfolio - potential partners don't want to be upstaged down the track.
Neuren’s second patented drug candidate, NNZ-2591, is a synthetic analogue of a naturally occurring neuropeptide, which has been shown to have neuroprotective and nootropic (memory enhancing) effects in multiple animal models. NNZ-2591 has shown encouraging results in wellvalidated preclinical models of cognitive impairment, Fragile X syndrome, traumatic brain injury, stroke, Parkinson’s disease, peripheral neuropathy and multiple sclerosis.
wtf?, page-61
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.60 |
Change
0.740(3.73%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $4.204M | 207.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 79 | $20.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.60 | 825 | 7 |
View Market Depth
| Last trade - 14.01pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |